摘要
A combination of the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab with mFOLFOX6 chemotherapy improves survival in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), according to results from an international Phase III clinical trial. In the BREAKWATER study of 637 participants, patients treated with encorafenib/cetuximab with mFOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) had a 51% lower risk of dying than patients treated with standard-of-care chemotherapy with or without bevacizumab, and also had a 47% lower risk of cancer progression. “Encorafenib plus cetuximab plus mFOLFOX6 is a practice-changing, new standard of care for people with metastatic colorectal with a BRAFV600E mutation,” said lead author Elena Elez, MD, PhD, Head of the Colorectal Cancer Group at the Vall d'Hebron Institute of Oncology in Barcelona, Spain, at the 2025 ASCO Annual Meeting. Background BRAFV600E mutations occur in 8% to 12% of patients with mCRC. The disease carries a poor prognosis, and first-line standard-of-care chemotherapy has limited efficacy. Encorafenib is a highly selective, ATP-competitive inhibitor that combined with cetuximab was first approved in 2020 for BRAFV600E-mutant mCRC in second-line and later-line settings based on results from the BEACON study. BREAKWATER evaluated the targeted therapy combination with or without mFOLFOX6 vs. standard care in previously untreated BRAF V600E-mutant mCRC. Previously, BREAKWATER met one of its dual primary endpoints by demonstrating clinically meaningful and statistically significant improvement in confirmed overall response rate (ORR), and the FDA granted accelerated approval for encorafenib plus cetuximab and mFOLFOX6 in patients with BRAFV600E-mutant mCRC, including the first-line setting. Before BREAKWATER, there were no approved biomarker-driven therapies specifically indicated for patients with previously untreated BRAFV600E-mutant mCRC, Elez said. About the Study The BREAKWATER study originally included three treatment arms: encorafenib/cetuximab alone (158 patients), encorafenib/cetuximab with mFOLFOX6 (236 patients), and the control arm of chemotherapy with or without bevacizumab (243 patients). When early results showed that the encorafenib/cetuximab with mFOLFOX6 arm had a statistically significant improvement in ORR, enrollment in the encorafenib/cetuximab alone arm was closed in a protocol amendment. Newly reported results show overall survival (OS) was 30.3 months in the encorafenib/cetuximab with mFOLFOX6 arm, 19.5 months in the encorafenib/cetuximab alone arm, and 15.1 months in the control arm. Progression-free survival (PFS) was 12.8 months in the encorafenib/cetuximab plus mFOLFOX6 arm, 6.8 months in the encorafenib/cetuximab alone arm, and 7.1 months in the control arm. ORR was 65.7% in the encorafenib/cetuximab plus mFOLFOX6 arm, 45.6% in the encorafenib/cetuximab alone arm, and 37.4% in the control arm. The median duration of response was 13.9 months with the triplet combination vs. 10.8 months with standard of care. Most of the side effects from these treatments were manageable, Elez noted. Serious side effects caused by the treatments occurred in 30% of patients in the encorafenib/cetuximab-alone arm, 46% of the encorafenib/cetuximab with mFOLFOX6 arm, and 39% of the control arm. The most common side effects for the encorafenib/cetuximab with mFOLFOX6 treatment were nausea, anemia, and diarrhea. Researchers will continue to study the encorafenib/cetuximab combination with another chemotherapy regimen, FOLFIRI, which combines the common chemotherapy drugs folinic acid, fluorouracil, and irinotecan. “The BREAKWATER study has met both of its primary dual endpoints and the key secondary endpoint,” Elez noted. “PFS data demonstrated statistically significant and clinically meaningful improvement. This second interim analysis of OS also demonstrated statistically significant and clinically meaningful improvement. The safety data continued to show that encorafenib plus cetuximab plus mFOLFOX6 was generally tolerable, with a safety profile consistent with that known for each agent and no substantial increase in chemotherapy dose reduction or discontinuation vs. standard of care.” Joel Saltzman, MD, ASCO Expert in gastrointestinal cancers and Vice Chair of Regional Oncology at the Taussig Cancer Center in the Cleveland Clinic, commented, “This trial continues to move the needle forward to a more personalized approach to care based on the molecular and genetic characteristics of metastatic colon cancer. This trial establishes frontline encorafemib, cetuximab, and FOLFOX as the new standard of care for BRAFV600E-mutant metastatic colorectal cancer.” Mark L. Fuerst is a contributing writer.